| Literature DB >> 25804908 |
Hui Jing1, Hening Lin1.
Abstract
Mesh:
Substances:
Year: 2015 PMID: 25804908 PMCID: PMC4610301 DOI: 10.1021/cr500457h
Source DB: PubMed Journal: Chem Rev ISSN: 0009-2665 Impact factor: 60.622
Figure 1Enzymatic function of sirtuins. (A) NAD-dependent protein lysine deacylation activity of different sirtuins. (B) Enzymatic reaction mechanism of sirtuins. (C) Structure of a ternary sirtuin-NAD-acetyl peptide complex (PDB ID 2H4F). NAD, acetyl lysine, and the key catalytic His residue are shown in stick representation. Bound zinc is shown as a gray sphere. Protein structure picture is generated using PyMol.
Figure 2Models for the role of SIR2 in gene silencing in yeast. (A) SIR2 and SIR complex at the silent mating-type loci and telomeric heterochromatin. (B) SIR2 at silenced rDNA loci.
SIRT1 Deacetylation Substrates
| substrate | full name | site of modifications | function of SIRT1-catalyzed deacetylation |
|---|---|---|---|
| histones | |||
| H1 | histone H1 | K26 | promote the formation of
heterochromatin and transcriptional repression[ |
| H3 | histone H3 | K9, K14, K56 | deacetylation of H3K9 and
H3K14 promotes transcriptional repression and heterochromatin formation;[ |
| H4 | histone H4 | K16 | promote the formation of
heterochromatin and transcriptional repression[ |
| chromatin modifying enzyme and structural proteins | |||
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | K160, K188, K259, K366, K749, K891, K957, K961, K975, K1054, K1111, K1113, K1115, K1117, K1349, K1415 | deacetylation
of K1349 and
K1415 in the catalytic domain increases DNMT1 activity; deacetylation
of lysine residues in the GK linker decreases DNMT1’s methyltransferase-independent
transcriptional repression function; deacetylation of all identified
acetylated lysine sites in DNMT1 abrogates its binding to SIRT1 and
impairs its capability to regulate cell cycle G2/M transition[ |
| HDAC1 | histone deacetylase 1 | K89, K220, K432, K438, K439, K441 | stimulate HDAC1
activity
after DNA double-strand break (DSB) induction, which is critical for
DSB repair by the nonhomologous end-joining pathway[ |
| hMOF | human ortholog of MOF | K274 | increase the chromatin recruitment
of hMOF to |
| P300 | K1020, K1024 | repress its transactivation[ | |
| PCAF | histone acetyltransferase KAT2B | unknown | repress its transactivation
and retard muscle differentiation in response to redox stress[ |
| SATB1 | DNA-binding protein SATB1 | K136, K175 | facilitate the inter-MAR
(matrix attachment region) association and to promote ε-globin
gene expression[ |
| SUV39H1 | suppressor of variegation 3–9 homologue 1 | K266 | upregulate the methyltransferase
activity of SUV39H1[ |
| TIP5 | transcription termination factor I-interacting protein 5 | K633 | promote the binding of NoRC
with promoter RNA (pRNA) and increase the heterochromatin histone
marks at rDNA loci[ |
| TIP60 | 60 kDa Tat-interactive protein | K327 | inhibit the acetyltransferase
activity and protein stability of TIP60[ |
| transcription factors | |||
| AR | androgen receptor | K630, K632, K633 | repress dihydrotestosterone
(DHT)-induced AR signaling by inhibiting coactivator-mediated interaction
between the AR N- and C-termini[ |
| BMAL1 | brain and muscle ARNT-like 1 | K537 | keep CRY from binding to
BMAL1 and facilitate transactivation of CLOCK/BMAL1[ |
| c-JUN | proto-oncoprotein c-JUN | K268, K271, K273 | inhibit the
activity of
transcription factor AP-1, leading to T-cell anergy and diminished
T-cell activation[ |
| c-MYC | proto-oncoprotein c-MYC | K323 | facilitate c-MYC/MAX interaction
and stabilize c-MYC, leading to increased c-MYC transactivation activity,[ |
| CIITA | class II transactivator | unknown | shield CIITA from proteasomal
degradation and promote its nuclear accumulation and transactivation
on MHC II (major histocompatibility complex II) during antigen-dependent
T-cell stimulation[ |
| CRTC1 | CREB-regulated transcription coactivator 1 | K13, K20, K33, K178, K197 | activate CRTC1 by facilitating
its dephosphorylation and interaction with CREB, thus activating the
transcriptional networks in both the normal and the Huntington’s
disease brain[ |
| CRTC2 | CREB regulated transcription coactivator 2 | K628 | destabilize CRTC2, resulting
in decreased CRTC2/CREB-mediated gluconeogenesis during long-term
fasting[ |
| DCOH2 | dimerization cofactor of HNF-1α | promotes its dimerization
with hepatocyte nuclear factor 1alpha (HNF-1α), leading to increased
DNA binding of HNF-1α and intestinal farnesoid X receptor (FXR)
signaling, and subsequent alteration of systemic bile acid homeostasis[ | |
| E2F1 | E2F transcription factor 1 | K117, K120, K125 | inhibit E2F1 transcriptional
and apoptotic activity in response to DNA damage[ |
| ERα | estrogen receptor α | K266, K268 | increase[ |
| FOXA2 | forkhead box protein A2 | K6, K259, K264, K273, K275 | target FOXA2 toward proteasomal
degradation and inhibit FOXA2-mediated fatty acid oxidation and ketogenesis
during fasting;[ |
| FOXO1 | forkhead box protein O1 | K242, K245, K262 | promote FOXO1-mediated transcription
during gluconeogenesis,[ |
| FOXO3a | forkhead box protein O3a | unknown | inhibit its transcription
activation and ability to induce apoptosis[ |
| FOXO4 | forkhead box protein O4 | unknown | activate FOXO4-dependent
transcription of stress-regulating genes[ |
| FOXP3 | forkhead box protein P3 | unknown | lead to FOXP3 polyubiquitination
and proteosome-mediated degradation and decreased numbers of regulatory
T cells[ |
| FXR | farnesoid X receptor | K217 | decrease its stability but
promote heterodimerization with RXRα, DNA binding, and transactivation
activity,[ |
| HIF-1α | hypoxia-inducible factor 1α | K674 | repress the transactivation
of HIF-1α during hypoxia[ |
| HIF-2α | hypoxia-inducible factor 2α | K385, K685, K741 | activate HIF-2α,
thereby
promoting HIF-2 signaling during hypoxia[ |
| HSF-1 | heat shock factor 1 | K80 | prolong HSF-1 binding to
the heat shock promoter;[ |
| LXRα | liver X receptor protein α | K432 | activate LXRα, leading
to increased expression of various LXR targets involved in lipid metabolism[ |
| MeCP2 | methyl-CpG binding protein 2 | K464 | deacetylation keeps it from
binding to the brain-derived neurotrophic factor (BDNF) promoter in
hippocampi[ |
| MyoD | myogenic determining factor | K99, K102, K104 | repress its transactivation
and retard muscle differentiation in response to redox stress[ |
| NFAT | nuclear factor of activated T cells | unknown | suppress the transcriptional
activity of NFAT, leading to the inhibition of PMA/lonomycin-induced
expression of COX-2[ |
| NHLH2 | helix–loop–helix protein 2 | K49 | SIRT1 deacetylates NHLH2
to activate the monoamine oxidase A (MAO-A) promoter, thereby decreasing
serotonin levels in the brain[ |
| NOTCH | neurogenic locus notch homologue protein 1 | K1764, K1770, K1771, K1772, K1785, K1935, K2050, K2068, K2146, K2147, K2150, K2154, K2161, K2164 | destabilize NOTCH, thereby
limiting the DDL4/NOTCH signaling in endothelial cells[ |
| NPM1 | nucleophosmin 1 | K212, K215, K229, K230, K257, K267 | reduce
its activity to promote
transcription of genes implicated in oral cancer[ |
| p53 | tumor suppressor p53 | K382 | negatively regulate transactivation
activity of p53, thereby attenuating p53-dependent apoptosis induced
by DNA damage and oxidative stress,[ |
| p73 | tumor protein p73 | unknown | suppress p73-dependent transactivation[ |
| PER2 | period circadian protein homologue 2 | unknown | promote the degradation
of PER2, thereby derepressing CLOCK/BMAL1-mediated expression of circadian
clock gene expression[ |
| PGC-1α | peroxisome proliferator-activated receptor-γ coactivator 1α | K77, K144, K183, K253, K277, K270, K320, K346, K412, K441, K450, K757, K778 | stimulate its transcription
coactivator activity on mediating gluconeogenesis,[ |
| PTF1A | pancreatic transcription factor-1a | unknown | SIRT1 colocalizes with PTF1A
at the acinar gene promoters and promotes acinar-to-ductal metaplasia[ |
| RARβ | retinoic acid receptor-β | unknown | activate RARβ and
promote the transcription of the α-secretase gene ADAM10, thereby
inhibiting β-amyloid production[ |
| RelA/p65 | RelA/p65 subunit of nuclear factor-κB | K310 | repress NF-κB-dependent
transcription, augmenting TNFα-induced apoptosis[ |
| RFX5 | regulatory factor for X-box RFX5 | unknown | promote its nuclear exclusion
and proteasomal degradation, thereby derepressing collagen type I
(COL1A2) transcription by RFX5 in smooth muscle cells[ |
| SMAD3 | mothers against decapentaplegic homologue 3 | unknown | repress the transactivation
of SMAD3 following TGF-β1 in a chronic kidney disease (CKD)
model[ |
| SMAD4 | mothers against decapentaplegic homologue 4 | unknown | repress the effect of TGF-β
signaling on MMP7 and therefore the EMT transition in cancer metastasis[ |
| SMAD7 | mothers against decapentaplegic homologue 7 | K64, K70 | promote SMAD
ubiquitination
regulatory factor 1 (Smurf1)-mediated proteasome degradation and TGF-β-induced
apoptosis in glomerular mesangial cells[ |
| SREBP-1c | sterol regulatory element-binding protein 1c | K289, K309 | inhibits its
transactivation
by destabilizing it and reducing its binding affinity for promoters
of lipogenic target genes[ |
| STAT3 | signal transducer and activator of transcription 3 | K679, K685, K707, K709 | repress the inhibitory effect
of STAT3 on gluconeogenic gene expression during long-term fasting[ |
| STAT5 | signal transducer and activator of transcription 5 | K681, K694, K701, K705 | negatively regulate GH-induced
STAT5 phosphorylation and IGF-I production during fasting in the liver[ |
| TAFI68 | TATA box-binding protein-associated factor RNA polymerase I subunit B | unknown | decrease its DNA-binding
activity and repress RNA polymerase I transcription[ |
| TAT | human immunodeficiency virus (HIV) TAT protein | K50 | SIRT1 deacetylates
TAT and
acts as a transcriptional coactivator during Tat-mediated transactivation
of HIV long terminal repeat[ |
| YAP2 | mammalian Ste20-like kinase/Yes-associated protein 2 | K76, K90, K97, K102 | increase
the YAP2/TEAD4
(TEA Domain Family Member 4) association in hepatocellular carcinoma
(HCC) cells, resulting in YAP2/TEAD4 transcriptional activation and
increase in cell growth[ |
| β-catenin | β-catenin | K49, K345 | promote its translocation
from nucleus to cytoplasm and destabilize it, limiting its ability
to activate transcription and drive cell proliferation;[ |
| DNA damage repair-related substrates | |||
| APE1 | apurinic/apyrimidinic endonuclease-1 | K6, K7 | promote base excision
repair
of damaged DN.[ |
| KU70 | DNA repair factor KU70 | K539, K542 | cause it to sequester the
pro-apoptotic factor Bax (BCL2-Associated X Protein) away from mitochondria,
thus inhibiting stress-induced apoptotic cell death;[ |
| MCM10 | protein MCM10 homologue | K312, K390, K683, K745, K761, K768, K681 + K682, K737 + K739, K847 + K849, K868 + K874, K683 + K685, K674 + K682 | modulate its stability and
ability to bind DNA; promote its function in DNA replication fork
initiation[ |
| NBS1 | Nijmegen Breakage Syndrome 1 | unknown | deacetylation of NBS1 is
required for ionizing radiation-induced NBS1 phosphorylation at Ser343,
which is essential for the activation of S phase checkpoint and for
efficient DNA damage repair response[ |
| WRN | Werner syndrome ATP-dependent helicase | unknown | promote its helicase and
exonuclease activities and facilitate its translocation from nucleoplasm
to nuclei in response to DNA damage[ |
| XPA | xeroderma pigmentosum group A | K63, K67 | SIRT1-mediated deacetylation
of XPA is essential for optimal nucleotide excision repair (NER) pathway
during UV-induced DNA repair[ |
| other substrates | |||
| AceCS1 | acetyl-CoA synthetase 1 | K661 | activate AceCS1 to convert
acetic acid to acetyl-CoA for use in fatty acid synthesis[ |
| AKT | RAC-alpha serine/threonine-protein kinase | unknown | activate AKT and promote
axonogenesis[ |
| ATG5 | autophagy-related protein 5 | unknown | promote the induction of
autophagy[ |
| ATG7 | autophagy-related protein 7 | unknown | promote the induction of
autophagy[ |
| ATG8 | autophagy-related protein 8 | unknown | promote the induction of
autophagy[ |
| BCL6 | B-cell lymphoma 6 protein | K379 | activate its oncogenic activit.[ |
| cortactin | cortactin | unknown | facilitate cancer cell migration[ |
| CREB | cAMP response element binding protein | K136 | repress its activity by
preventing its phosphorylation, which leads to decreased expression
of gluconeogenic genes and increased hepatic lipid accumulation and
secretion[ |
| eNOS | endothelial nitric oxide synthase | K496, K506 | activate eNOS in the cytoplasma,
which increases NO level, leading to vasodilatation, increased blood
flow, and nutrient delivery to tissues[ |
| EVI1 | ectopic viral integration site I | unknown | lead to destabilization
of the protein[ |
| HMGB1 | high-mobility group box 1 | K55, K88, K90, and K177 | repression
of SIRT1 induced
by inflammation disables deacetylation of HMBG1 and promotes the nuclear-to-cytoplasmic
translocation and release into circulation, thereby maintaining inflammation[ |
| HMGCS1 | hydroxymethylglutaryl-CoA synthase 1 | unknown | unknown[ |
| IRS-1 | insulin receptor substrate 1 | unknown | promote systemic insulin
resistance in neurons[ |
| IRS-2 | insulin receptor substrate 2 | unknown | promote its phosphorylation
and activate the IGF-1/Ras/ERK1/2 pathway,
sensitizing neurons to oxidative damage[ |
| LIN28 | protein LIN-28 | unknown | restore its stability[ |
| MMP2 | matrix metalloproteinase-2 | unknown | stabilize MMP2, thereby
increasing tumor cell invasion in prostate cancer[ |
| PARP1 | poly(ADP-ribose) polymerase 1 | K498, K505, K508, K521, K524 | attenuate PARP1
activity
and protect cells from PARP1-dependent cell death under stress conditions[ |
| PGAM1 | glycolytic enzyme phosphoglycerate mutase-1 | K251, K253, K254 | decrease PGAM1
activity
in glycolysis[ |
| PIP5Kγ | phosphatidylinositol-4-phosphate 5-kinase gamma | K265, K268 | activate PIP5Kγ
and
promote the secretion of thyroid stimulating hormone (TSH) from pituitary
cells[ |
| PTEN | phosphatase and tensin homologue | unknown | SIRT1 deacetylates PTEN
to inhibit AKT and trigger apoptosis under antioxidant-free conditions[ |
| RB | retinoblastoma tumor suppressor protein | K873, K874 | allow phosphorylation of
RB and relieve RB-mediated repression of E2F-regulated cell cycle
genes[ |
| S6K1 | p70 ribosomal S6 kinase | K484, K485, K493 | decrease the Thr-389 phosphorylation
and kinase activity of S6K1[ |
| Tau | microtubule-associated protein tau | unknown | destabilize tau protein,
resulting in the decrease in tau protein aggregates[ |
| TDG | thymine DNA glycosylase | unknown | increase TDG glycosylase
activity and weakly shift its activity toward T/G, 5-formylcytosine/G,
and 5-carboxylcytosine/G compared from 5-fluorouracil/G[ |
| TIAM1 | T-cell lymphoma invasion and metastasis 1 | K1420 | promotes activation of DVL/TIAM1/Rac
axis and cell migration in cancer cells[ |
| zyxin | zyxin | unknown | SIRT1 deacetylates Zyxin
and modulates its activity upon treatment with leptomycin B[ |
| 14-3–-3ζ | 14-3-3ζ | K49, K157, K212 | keep 14-3-3ζ from dissociating from caspase-2, thereby
antagonizing
caspase-2-dependent apoptosis[ |
Figure 3Model for SIRT1-mediated heterochromatin formation and transcriptional silencing.
SIRT2 Deacetylation Substrates
| substrate | full name | modified lysine residues | function of SIRT2-catalyzed deacetylation |
|---|---|---|---|
| histones | |||
| H4 | histone H4 | K16 | regulate chromatin condensation
during metaphase, regulate H4K20 methylation, promote cell cycle progression
and genome stability; suppress transcription of certain genes[ |
| H3 | histone H3 | K18 | |
| K56 | unclear, may be involved in DNA damage repair | ||
| transcription factors | |||
| P300 | many | promote binding of p300
to preinitiation complex[ | |
| FOXO3 | forkhead box protein O3 | unknown | increase FOXO3 DNA binding
and target gene transcription;[ |
| FOXO1 | forkhead box protein O1 | unknown | promote FOXO1 interaction
with PPARγ and repress PPARγ target genes;[ |
| HIF-1α | hypoxia-inducible factor 1α | K709 | promote hydroxylation and
degradation of HIF-1α[ |
| NF-κB | nuclear factor κ B | K310 | suppress NF-κB-dependent
gene expression[ |
| PGC-1α | peroxisome proliferator-activated receptor-γ coactivator 1α | unknown | decrease expression of β-oxidation
and mitochondrial genes[ |
| cell cycle related | |||
| BubR1 | mitotic checkpoint serine/threonine-protein kinase BUB1 β | K688 | stabilize
BubR1, improve
cardiac function, and extend lifespan in vivo[ |
| CDK9 | cyclin-dependent kinase 9 | K48 | increase CDK9 kinase activity
and decrease sensitivity to hydroxylurea-induced replication stress
response[ |
| CDH1/CDC20 | CDH1/cell-division cycle protein 20 | K69 and K159 (CDH1), K66 (CDC20) | activate
the E3 ubiquitin
ligase activity, leading todecreased Aurora A level[ |
| metabolic enzymes | |||
| LDH-A | lactate dehydrogenase A | K5 | activates LDH-A[ |
| PEPCK | phosphoenolpyruvate carboxykinase | K70, K71 | inhibit the ubiquitinylation
and degradation of PEPCK[ |
| ACLY | ATP-citrate lysase | K540, K546, K554 | promote ATP-citrate lyase
degradation[ |
| G6PD | glucose-6-phosphate dehydrogenase | K403 | promote the formation of
active G6PD dimer and increase NADPH production[ |
| PGAM | phosphoglycerate mutase | K100 | activate PGAM activity[ |
| cell signaling related | |||
| PRLR | prolactin receptor | many | facilitate
prolactin receptor
dimerization and activation of STAT5[ |
| K-Ras | Kirsten rat sarcoma viral oncogene homologue | K104 | promote K-Ras
activity[ |
| PAR-3 | partitioning defective 3 homologue | K831, K848, K881, K1327 | decrease
the activity of
aPKC and regulate myelin formation[ |
| TIAM1 | T-cell lymphoma invasion and metastasis 1 | K1420 | promote activation of DVL/TIAM1/Rac
axis and cell migration in cancer cells[ |
| structural proteins | |||
| keratin 8 | keratin 8 | K207 | affect its phosphorylation
and filament organization[ |
| α-tubulin | α-tubulin | K40 | destabilize microtubule[ |
Comparison of the Deacetylation and Defatty-Acylation Activities of SIRT6
| acyl peptide | |||
|---|---|---|---|
| H3K9 acetyl | 0.0039 ± 0.0006[ | 810 ± 160[ | 4.8[ |
| H3K9 acetyl with myristic acid | ∼0.002[ | 9 ± 1[ | 230 ± 30 |
| H3K9 myristoyl | 0.0049 ± 0.0004[ | 3.4 ± 0.9[ | 1.4 × 103[ |
| H3K9 palmitoyl | 0.0027 ± 0.0002[ | 0.9 ± 0.4[ | 3.0 × 103[ |